Search

Your search keyword '"Röllig, Christoph"' showing total 1,071 results

Search Constraints

Start Over You searched for: Author "Röllig, Christoph" Remove constraint Author: "Röllig, Christoph"
1,071 results on '"Röllig, Christoph"'

Search Results

1. How to customize common data models for rare diseases: an OMOP-based implementation and lessons learned

2. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

4. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia

5. Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML

6. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia

7. Biallelic TET2 mutation sensitizes to 5’-azacitidine in acute myeloid leukemia

8. Prognostic impact of CEBPA mutational subgroups in adult AML

9. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial

10. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

11. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

12. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience

13. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

14. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

15. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

16. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

17. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

18. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

19. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy

20. Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML)

21. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia

22. Overlapping features of therapy-related and de novo NPM1-mutated AML

23. Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3AmutNPM1mut AMLs

26. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1

27. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

28. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial

29. Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse

31. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

32. Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

33. The proteogenomic subtypes of acute myeloid leukemia

34. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

35. Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries

36. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

37. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

38. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

39. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

40. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

41. Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.

44. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

45. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

46. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

48. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries

49. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

50. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial

Catalog

Books, media, physical & digital resources